Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xuesong Yu

Showing results (41-50 of 46) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 46 results.
Plos One|July 21, 2017
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, et al.
International Journal of Clinical Oncology|January 21, 2026
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinomaEiji Kikuchi, Michiel S Van der Heijden, Begoña P Valderrama, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
The New England Journal of Medicine|March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerThomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Future Oncology (London, England)|January 31, 2025
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 studyThomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Journal of Virology|February 17, 2017
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell ResponsesGerard Zurawski, Xiaoying Shen, Sandra Zurawski, et al.
Pageof 5

Showing results (41-50 of 46) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 46 results.
Plos One|July 21, 2017
Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adultsSusan P Buchbinder, Nicole A Grunenberg, Brittany J Sanchez, et al.
International Journal of Clinical Oncology|January 21, 2026
Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinomaEiji Kikuchi, Michiel S Van der Heijden, Begoña P Valderrama, et al.
Plos One|May 10, 2016
Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.
The New England Journal of Medicine|March 6, 2024
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial CancerThomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Future Oncology (London, England)|January 31, 2025
A study to learn how well enfortumab vedotin (EV) with pembrolizumab works and how safe it is in people with advanced urothelial cancer: a plain language summary of the EV-302/KEYNOTE-A39 studyThomas Powles, Begoña P Valderrama, Shilpa Gupta, et al.
Journal of Virology|February 17, 2017
Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell ResponsesGerard Zurawski, Xiaoying Shen, Sandra Zurawski, et al.
Pageof 5